Overview

An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event

Status:
Completed

Trial end date:
2010-04-23

Target enrollment:

Participant gender:

Summary

Primary Objective: To document the tolerability of patients receiving study medication at 12-week of therapy in terms of the scoring system assessed by the investigator. Secondary Objectives: - To document drug safety at 12-week of treatment in terms of number of Adverse Drug Reaction or Serious Adverse Drug Reaction reported. - To describe the population treated as per the HOPE study indication in current clinical practice (demographics, cardiovascular risk-factors at treatment initiation, concomitant treatments patterns).

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Ramipril